<DOC>
	<DOCNO>NCT00764036</DOCNO>
	<brief_summary>The purpose study evaluation tolerability add-on therapy artesunate duration 4 week patient advance breast cancer .</brief_summary>
	<brief_title>Study Artesunate Metastatic Breast Cancer</brief_title>
	<detailed_description>Additional objective : - parallel sample blood saliva determination drug concentration pharmacokinetic parameter substudy day first application steady state - attempt establish therapeutical drug monitoring - collection safety data prolong add-on treatment ( compassionate use )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Patients histologically cytologically confirm breast cancer Distant metastases locally advanced breast cancer Age ≥ 18 year ECOG performance ≤ 2 Life expectancy least 6 month Written inform consent individual standard therapy accord guideline Oral intake trial medication possible Compliance study procedure Women childbearing potential : negative pregnancy test start medication Use highly effective method birth control intake addon therapy woman childbearing potential sexually active Inclusion Criteria Extended Treatment Phase : Participant phase I study ARTIC M33/2 tolerate study medication 4±1 week without clinically relvant adverse event improvement ≤ grade 2 Participant phase I study ARTIC M33/2 possible benefit continuation restart addon therapy next progression accord current scientific knowledge Written inform consent extend treatment phase Consent responsible oncologist Compliance intake followup expect Inclusion Criteria Individual Compassionate Use : Participant phase I study ARTIC M33/2 Available standard therapy minimal short activity intolerable side effect Written inform consent compassionate use Consent responsible oncologist Allergy artesunate artemisinin derivative Concurrent condition interfere patient safety Communication problem Concurrent participation another clinical trial 4 week prior recruitment Participation clinical trial unapproved drug 6 month prior recruitment Sinus bradycardia , bradyarrhythmia AVBlock II° III° QTc &gt; 500 msec Previously know long QTsyndrome Concurrent intake medication clinically relevant neurotoxicity 30 day prior recruitment Relevant neurological symptom might complicate evaluation compatibility IMPD ( f. e. cerebral metastasis ) might subject worsen intake IMPD Radiotherapy 2 week prior intake IMPD Concurrent intake supplement medication unapproved efficacy f.e . vitamin , mineral others ( OTC ) Pregnancy lactation Ineffective mode contraception woman childbearing potential Exclusion Criteria Extended Treatment Phase : Clinically relevant adverse Events first 4 week intake study medication possibly , probably definitely relate study medication Intolerable health risk continuation reexposition study medication Continuation reexposition medically acceptable consultation physician responsible standard therapy Exclusion Criteria Individual Compassionate Use : Intolerable health risk reexposition study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>phase I</keyword>
	<keyword>safety</keyword>
</DOC>